drugset / Trial / NCT05358548
ATATcH Alternating Treatment Plans for Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Timeline
- Start
- 2022-04-28
- Primary completion
- 2027-05-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |